Cancer

Novel Artificial Intelligence Method Predicts Future Risk of Breast Cancer : Researchers

  • Posted on: 16 May 2019
  • By: Shalini.Sharma

Researchers from two major institutions have developed a new tool with advanced artificial intelligence (AI) methods to predict a woman’s future risk of breast cancer, according to a new study published in the journal Radiology.

Senior Scientific Officer require in National Institute of Cancer prevention and research

National Institute of Cancer prevention and research (NICPR) was initially established as Cytology Research Centre (CRC) by the Indian Council of Medical Research (ICMR) in 1979, and was elevated to the level of an Institute in 1989. It was granted national status in 2016 acknowledging its mandate and contributions towards cancer prevention. The institute has broadened its horizon to cater to prevention of prevalent cancers in the country.

Job for Life Sciences Post Graduate at National Institute of Immunology

The National Institute of Immunology (NII) is committed to advanced research addressing the basic mechanisms involved in body's defence to identify modalities for manipulation of the immune system to provide protection against diseases and understand mechanisms that can be used to target disease processes for intervention. The institute’s research thrust areas under immunology and related disciplines cluster in four main themes, namely, infection and immunity, molecular design, gene regulation and reproduction and development, where cutting edge research in modern biology is being carried out.

Post : Junior Research Fellow/Senior Research Fellow & Data Entry Operator (Project)

FDA approves first treatment for advanced form of the second most common skin cancer

  • Posted on: 1 October 2018
  • By: Shalini.Sharma

The U.S. Food and Drug Administration approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC.

EMERGING TRENDS IN ONCOLOGY CLINICAL TRIALS

ABOUT AUTHOR
DR. PRANJAL BORDOLOI
VP – PHARMACOLGY & COD
VEEDA CLINICAL RESEARCH PVT LTD.
info@veedacr.com

Therapeutic innovation in cancer treatment has always been in focus. Based on WHO data, worldwide, there were 14.1 million new cancer cases, 8.2 million cancer deaths, and 32.6 million people living with cancer within 5 years of diagnosis by year 2012. Top 5 most frequent cancers in world (ranked by number of new cases) are breast, prostate, lung, colorectal, and cervical cancers per 2012 WHO data (International Agency for Research on Cancer, WHO). For countries like India, the top 5 most frequent cancers (ranked by number of new cases) are breast, cervical, oral cavity, lung and colorectal cancers (International Agency for Research on Cancer, WHO). Reported age-adjusted incidence rates for cancer are still quite low in the demographically young country. Little more than 1 million new cases of cancer are diagnosed every year in India. An estimated 600 000–700 000 deaths in India were caused by cancer in 2012. In age-standardized terms this is close to the mortality burden seen in high-income countries. Such figures are somewhat indicative of low rates of early-stage detection and poor treatment outcomes (Mallath MK, et al. 2014).

Liver cells with whole Genome duplications protect against Cancer : Researchers

  • Posted on: 12 February 2018
  • By: pharmatutor.org

Researchers at the Children's Medical Center Research Institute (CRI) at UT Southwestern have discovered that cells in the liver with whole genome duplications, known as polyploid cells, can protect the liver against cancer. The study, published online today in Developmental Cell, addresses a long-standing mystery in liver biology and could stimulate new ideas to prevent cancer.

Myriad’s BRACAnalysis CDx® Identified Metastatic Breast Cancer Patients with Improved from Pfizer's PARP Inhibitor

  • Posted on: 13 December 2017
  • By: PharmaTutor News

Myriad Genetics, Inc. a leader in molecular diagnostics and personalized medicine, announced that data from the EMBRACA trial showed Myriad’s BRACAnalysis CDx®  test successfully identified patients with metastatic breast cancer (MBC) who responded to Pfizer’s investigational PARP inhibitor, talazoparib. 

A REVIEW ON: PLANTS AS ANTICANCER

{ DOWNLOAD AS PDF }

ABOUT AUTHOR
JY Manure, NS Naikwade
Department Of Pharmaceutical Chemistry
Appasaheb Birnale College of Pharmacy,
Sangli, Maharashtra, India
Javeedmanure.98600@yahoo.com

ABSTRACT 
Cancer is a diseases characterized by out-of-control cell growth. There are various types of cancer, and is classified by the type of cell that is affected. Cancer harms the body when altered cells divide uncontrollably to form lumps or masses of tissue called tumors. The recent treatments include chemotherapy, radiotherapy and Surgery. But this treatment accomplished by several side effect like the destruction of bone marrow cell, alopecia etc. So there is a need for the new drug for treatment of cancer. Plant-derived chemical may act as anticancer in many studies. The Plant produces secondary metabolites which are being evaluated for the anticancer activities leading to the development of new drugs. So in this review we have study different plants which act as anticancer. And this will encourage further scientific study of traditionally used plants.

Regional Centre for Biotechnology opens for M.Pharm / M.Sc professionals for cancer research

Regional Centre for Biotechnology (RCB), an institution of education, training and research is established by the Department of Biotechnology, Government of India under the auspices of UNESCO. The Centre will focus on cooperatively working towards shared biotechnology growth in the Asia-Pacific Region. Regional interactions in biotechnology will promote co-operation amongst the countries to develop necessary infrastructure and capacity building for economic benefit of our societies.

Pages